Search

Your search keyword '"Gupta, P."' showing total 349 results
Start Over Author "Gupta, P." Journal journal of clinical oncology
349 results on '"Gupta, P."'

1. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.

Author

Hoimes, Christopher, Flaig, Thomas, Milowsky, Matthew, Bilen, Mehmet, Gupta, Shilpa, Srinivas, Sandy, Merchan, Jaime, McKay, Rana, Petrylak, Daniel, Sasse, Carolyn, Moreno, Blanca, Yu, Yao, Carret, Anne-Sophie, Rosenberg, Jonathan, and Friedlander, Terence

Subjects
Humans, Cisplatin, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Neoplasms
Abstract

PURPOSE: Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and many patients with la/mUC are ineligible. Each enfortumab vedotin and pembrolizumab have shown a survival benefit versus chemotherapy in UC, are not restricted by cisplatin eligibility, and warrant investigation as a first-line (1L) combination therapy in patients ineligible for cisplatin. METHODS: In this ongoing phase Ib/II, multicenter, open-label study, 1L cisplatin-ineligible patients with la/mUC received enfortumab vedotin 1.25 mg/kg once daily on days 1 and 8 and pembrolizumab 200 mg (day 1) intravenously once daily in 3-week cycles. The primary end point was safety. Key secondary end points included confirmed objective response rate, duration of response (DOR), and overall survival (OS). RESULTS: Forty-five patients received enfortumab vedotin plus pembrolizumab. The most common treatment-related adverse events (TRAEs) were peripheral sensory neuropathy (55.6%), fatigue (51.1%), and alopecia (48.9%). Twenty-nine patients (64.4%) had grade 3 or higher TRAEs; the most common were increased lipase (17.8%), maculopapular rash (11.1%), and fatigue (11.1%). One death (2.2%) was classified as a TRAE. The confirmed objective response rate after a median of nine cycles was 73.3% with a complete response rate of 15.6%. The median DOR and median OS were 25.6 months and 26.1 months, respectively. CONCLUSION: Enfortumab vedotin plus pembrolizumab showed a manageable safety profile. Most patients experienced tumor shrinkage. The median DOR and median OS exceeding 2 years in a cisplatin-ineligible patient population make this a promising combination currently under investigation in a phase III study (ClinicalTrials.gov identifier: NCT04223856).

Published
2023

2. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.

Author

Cornell, Robert, Ky, Bonnie, Weiss, Brendan, Dahm, Cherie, Gupta, Deepak, Du, Liping, Carver, Joseph, Cohen, Adam, Engelhardt, Brian, Garfall, Alfred, Goodman, Stacey, Harrell, Shelton, Kassim, Adetola, Jadhav, Trafina, Jagasia, Madan, Moslehi, Javid, OQuinn, Rupal, Savona, Michael, Slosky, David, Smith, Amanda, Stadtmauer, Edward, Vogl, Dan, Waxman, Adam, and Lenihan, Daniel

Subjects
Adult, Aged, Aged, 80 and over, Bortezomib, Cardiovascular Diseases, Disease-Free Survival, Electrocardiography, Female, Heart Diseases, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Molecular Targeted Therapy, Multiple Myeloma, Natriuretic Peptide, Brain, Neoplasm Recurrence, Local, Oligopeptides, Prospective Studies, Proteasome Inhibitors, Risk Factors, Time-to-Treatment, Treatment Outcome, Troponin I, Troponin T
Abstract

PURPOSE: Cardiovascular adverse events (CVAEs) can occur during proteasome inhibitor (PI) therapy. We conducted a prospective, observational, multi-institutional study to define risk factors and outcomes in patients with multiple myeloma (MM) receiving PIs. PATIENTS AND METHODS: Patients with relapsed MM initiating carfilzomib- or bortezomib-based therapy underwent baseline assessments and repeated assessments at regular intervals over 6 months, including cardiac biomarkers (troponin I or T, brain natriuretic peptide [BNP], and N-terminal proBNP), ECG, and echocardiography. Monitoring occurred over 18 months for development of CVAEs. RESULTS: Of 95 patients enrolled, 65 received carfilzomib and 30 received bortezomib, with median 25 months of follow-up. Sixty-four CVAEs occurred, with 55% grade 3 or greater in severity. CVAEs occurred in 51% of patients treated with carfilzomib and 17% of those treated with bortezomib (P = .002). Median time to first CVAE from treatment start was 31 days, and 86% occurred within the first 3 months. Patients receiving carfilzomib-based therapy with a baseline elevated BNP level higher than 100 pg/mL or N-terminal proBNP level higher than 125 pg/mL had increased risk for CVAE (odds ratio, 10.8; P < .001). Elevated natriuretic peptides occurring mid-first cycle of treatment with carfilzomib were associated with a substantially higher risk of CVAEs (odds ratio, 36.0; P < .001). Patients who experienced a CVAE had inferior progression-free survival (log-rank P = .01) and overall survival (log-rank P < .001). PI therapy was safely resumed in 89% of patients, although 41% required chemotherapy modifications. CONCLUSION: CVAEs are common during PI therapy for relapsed MM, especially with carfilzomib, particularly within the first 3 months of therapy. CVAEs were associated with worse overall outcomes, but usually, discontinuation of therapy was not required. Natriuretic peptides were highly predictive of CVAEs; however, validation of this finding is necessary before uniform incorporation into the routine management of patients receiving carfilzomib.

Published
2019

3. A phase III randomized, open-label study to establish the superiority of triple oral metronomic therapy (OMCT) used in addition to chemotherapy regimen (paclitaxel + carboplatin) over chemotherapy alone for the treatment of advanced unresectable head...

Author

Kapoor, Akhil, Gupta, Anuj, Sansar, Bipinesh, Mishra, Bal Krishna, Gupta, Pooja, Singh, Arpita, Kapoor, Ankita Rungta, Nanda, Sambit Swarup, Mukherji, Ashutosh, Kumari, Rukmeena, Pal, Ankita, Singh, Satyendra Narayan, Mishra, Aseem, Dhal, Ipsita, Vinayak, Kunal Ranjan, Dey, Somnath, Noronha, Vanita, Patil, Vijay Maruti, Banavali, Shripad Dinanath, and Prabhash, Kumar

Published
2024
Full Text
View/download PDF

9. Don't drop the baton: A multidisciplinary and interprofessional approach to improving transfer of accountability and information transfer (TOAI).

Author

Ali, Anum, Glinsky, Victoria, Macedo, Alyssa, Weatherby, Hilary, Bagnarol, Rebecca, Mak, Ernie, Acharya, Ishan, Hirsch, Ian, Sanz Garcia, Enrique, Costa, Ana Luisa, Grande, Claudia, Dawes, Pearlina, Hahn, Ezra, Leung, Eugene, Thyagu, Santhosh, Gupta, Vikas, Viswabandya, Auro, Julius, Anet, Krzyzanowska, Monika K., and Dhani, Neesha C.

Published
2024
Full Text
View/download PDF

11. Cluster randomized pilot of the Best Case/Worst Case-Geriatric Oncology (BC/WC-GeriOnc) communication tool for older adults with cancer.

Author

Wong, Melisa L., Lee Jr., Howard Jinsoo, DeBoer, Rebecca Jane, Suchman, Lauren, Litt, Henry Kazunaru, Nicosia, Francesca, Boscardin, W. John, Loh, Kah Poh, Walter, Louise Christie, Smith, Alexander K., Huang, Li-Wen, Lowenstein, Lisa M., Neuman, Heather B., Volk, Robert J., Hopkins, Judith O., Mohile, Supriya Gupta, Mercurio, Anne Marie, and Schwarze, Margaret L.

Published
2024
Full Text
View/download PDF

18. Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.

Author

Ramaswamy, Anant, Bhargava, Prabhat, Srinivas, Sujay, Kapoor, Akhil, Mishra, Bal Krishna, Gupta, Anuj, Mandavkar, Sarika, Kannan, Sadhana, Chaugule, Deepali, Patil, Rajshree, Parulekar, Manali, Nashikkar, Chaitali, Ankathi, Suman Kumar, Kaushal, Rajiv Kumar, Naughane, Deepali, Daddi, Anuprita, Mer, Neha, Shetty, Nitin, and Ostwal, Vikas

Published
2024
Full Text
View/download PDF

19. A phase II study of oral chlorophyllin in haemorrhagic cystitis secondary to radiation therapy for pelvic malignancies (CLARITY).

Author

Prakash, Gagan, Sharma, Deepak, Chopra, Supriya, Pal, Mahendra, Arora, Amandeep, Murthy, Vedang, Gurram, Lavanya, Mittal, Prachi, Maitre, Priyamvada, Joshi, Mahendra, Madki, Shiv, Kumar, Sharath, Bonkar Dethe, Shraddha, Gawad, Priyal, Chaturvedi, Pankaj, Ghanty, Tapan K, Gupta, Sudeep, Badwe, Rajendra A., Sandur, Santosh, and Gota, Vikram

Published
2024
Full Text
View/download PDF

21. Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).

Author

Kikuchi, Eiji, Gupta, Shilpa, Loriot, Yohann, Van Der Heijden, Michiel Simon, Bedke, Jens, Valderrama, Begoña Pérez, Flechon, Aude, Petrylak, Daniel P., De Santis, Maria, Galsky, Matt D., Lee, Jae Lyun, Swami, Umang, Sridhar, Srikala S., De Giorgi, Ugo, Wright, Phoebe, Lu, Yi-Tsung, Guan, Xuesong, Dillon, Ryan, Homet Moreno, Blanca, and Powles, Thomas

Published
2024
Full Text
View/download PDF

24. Application of artificial intelligence (AI) features of nuclear morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.

Author

Hammouda, Kamal, Gupta, Shilpa, Pathak, Tilak, Sonpavde, Guru P., Gibb, Ewan, Gupta, Sumati, Maughan, Benjamin L., Agarwal, Neeraj, McGregor, Bradley Alexander, Mossanen, Matthew, Diaz-Montero, C. Marcela, Black, Peter C., Weight, Christopher, Mirtti, Tuomas, Konety, Badrinath R., and Madabhushi, Anant

Published
2024
Full Text
View/download PDF

25. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Author

Chow, Laura QM, Haddad, Robert, Gupta, Shilpa, Mahipal, Amit, Mehra, Ranee, Tahara, Makoto, Berger, Raanan, Eder, Joseph Paul, Burtness, Barbara, Lee, Se-Hoon, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Weiss, Jared, Geva, Ravit, Lin, Chia-Chi, Chung, Hyun Cheol, Meister, Amy, Dolled-Filhart, Marisa, Pathiraja, Kumudu, Cheng, Jonathan D, and Seiwert, Tanguy Y

Subjects
Clinical Research, Cancer, Dental/Oral and Craniofacial Disease, Rare Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, B7-H1 Antigen, Carcinoma, Squamous Cell, Cohort Studies, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported. Patients and Methods Patients with R/M HNSCC, irrespective of PD-L1 or human papillomavirus status, received pembrolizumab 200 mg intravenously once every 3 weeks. Imaging was performed every 8 weeks. Primary end points were overall response rate (ORR) per central imaging vendor (Response Evaluation Criteria in Solid Tumors v1.1) and safety. Secondary end points included progression-free survival, overall survival, and association of response and PD-L1 expression. Patients who received one or more doses of pembrolizumab were included in analyses. Results Of 132 patients enrolled, median age was 60 years (range, 25 to 84 years), 83% were male, and 57% received two or more lines of therapy for R/M disease. ORR was 18% (95% CI, 12 to 26) by central imaging vendor and 20% (95% CI, 13 to 28) by investigator review. Median duration of response was not reached (range, ≥ 2 to ≥ 11 months). Six-month progression-free survival and overall survival rates were 23% and 59%, respectively. By using tumor and immune cells, a statistically significant increase in ORR was observed for PD-L1-positive versus -negative patients (22% v 4%; P = .021). Treatment-related adverse events of any grade and grade ≥ 3 events occurred in 62% and 9% of patients, respectively. Conclusion Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and yielded a clinically meaningful ORR with evidence of durable responses, which supports further development of this regimen in patients with advanced HNSCC.

Published
2016

27. VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma.

Author

Menon, Nandini Sharrel, Shah, Minit Jalan, Gupta, Tejpal, Sridhar, Epari, Chatterjee, Abhishek, Dasgupta, Archya, Sahu, Arpita, Sawant, Riddhi, Kapu, Venkatesh, Trikha, Mehak, Shah, Anokhi, Peelay, Zoya Ravish, Puranik, Ameya, Dev, Indraja, Jadhav, Monica, Moiyadi, Aliasgar, Shetty, Prakash, Sahay, Ayushi, Singh, Vikas Kumar, and Patil, Vijay Maruti

Published
2024
Full Text
View/download PDF

29. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.

Author

Gordan, John D., Kennedy, Erin B., Abou-Alfa, Ghassan K., Beal, Eliza, Finn, Richard S., Gade, Terence P., Goff, Laura, Gupta, Shilpi, Guy, Jennifer, Hoang, Hang T., Iyer, Renuka, Jaiyesimi, Ishmael, Jhawer, Minaxi, Karippot, Asha, Kaseb, Ahmed O., Kelley, R. Kate, Kortmansky, Jeremy, Leaf, Andrea, Remak, William M., and Sohal, Davendra P.S.

Published
2024
Full Text
View/download PDF

32. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Author

Massard, Christophe, Gordon, Michael S, Sharma, Sunil, Rafii, Saeed, Wainberg, Zev A, Luke, Jason, Curiel, Tyler J, Colon-Otero, Gerardo, Hamid, Omid, Sanborn, Rachel E, O'Donnell, Peter H, Drakaki, Alexandra, Tan, Winston, Kurland, John F, Rebelatto, Marlon C, Jin, Xiaoping, Blake-Haskins, John A, Gupta, Ashok, and Segal, Neil H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Urologic Diseases, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, B7-H1 Antigen, Biopsy, Female, Humans, Immunohistochemistry, Male, Middle Aged, Time Factors, Treatment Outcome, Urinary Bladder Neoplasms, Urothelium, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeTo investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on clinical response in patients with advanced urothelial bladder cancer (UBC).MethodsA phase 1/2 multicenter, open-label study is being conducted in patients with inoperable or metastatic solid tumors. We report here the results from the UBC expansion cohort. Durvalumab (MEDI4736, 10 mg/kg every 2 weeks) was administered intravenously for up to 12 months. The primary end point was safety, and objective response rate (ORR, confirmed) was a key secondary end point. An exploratory analysis of pretreatment tumor biopsies led to defining PD-L1-positive as ≥ 25% of tumor cells or tumor-infiltrating immune cells expressing membrane PD-L1.ResultsA total of 61 patients (40 PD-L1-positive, 21 PD-L1-negative), 93.4% of whom received one or more prior therapies for advanced disease, were treated (median duration of follow-up, 4.3 months). The most common treatment-related adverse events (AEs) of any grade were fatigue (13.1%), diarrhea (9.8%), and decreased appetite (8.2%). Grade 3 treatment-related AEs occurred in three patients (4.9%); there were no treatment-related grade 4 or 5 AEs. One treatment-related AE (acute kidney injury) resulted in treatment discontinuation. The ORR was 31.0% (95% CI, 17.6 to 47.1) in 42 response-evaluable patients, 46.4% (95% CI, 27.5 to 66.1) in the PD-L1-positive subgroup, and 0% (95% CI, 0.0 to 23.2) in the PD-L1-negative subgroup. Responses are ongoing in 12 of 13 responding patients, with median duration of response not yet reached (range, 4.1+ to 49.3+ weeks).ConclusionDurvalumab demonstrated a manageable safety profile and evidence of meaningful clinical activity in PD-L1-positive patients with UBC, many of whom were heavily pretreated.

Published
2016

33. Reply to C.T. Matava et al.

Author

Alexander, Sarah, Kairalla, John A., Gupta, Sumit, Hibbitts, Emily, Weisman, Hannah, Anghelescu, Doralina, Winick, Naomi J., Krull, Kevin R., Salzer, Wanda L., Burke, Michael J., Gore, Lia, Devidas, Meenakshi, Embry, Leanne, Raetz, Elizabeth A., Hunger, Stephen P., Loh, Mignon L., and Hardy, Kristina K.

Published
2024
Full Text
View/download PDF

35. Cytogenetic prognostication within medulloblastoma subgroups.

Author

Shih, David, Northcott, Paul, Remke, Marc, Korshunov, Andrey, Ramaswamy, Vijay, Kool, Marcel, Luu, Betty, Yao, Yuan, Wang, Xin, Dubuc, Adrian, Garzia, Livia, Peacock, John, Mack, Stephen, Wu, Xiaochong, Rolider, Adi, Morrissy, A, Cavalli, Florence, Jones, David, Zitterbart, Karel, Faria, Claudia, Schüller, Ulrich, Kren, Leos, Kumabe, Toshihiro, Tominaga, Teiji, Shin Ra, Young, Garami, Miklós, Hauser, Peter, Chan, Jennifer, Robinson, Shenandoah, Bognár, László, Klekner, Almos, Saad, Ali, Albrecht, Steffen, Fontebasso, Adam, Cinalli, Giuseppe, De Antonellis, Pasqualino, Zollo, Massimo, Cooper, Michael, Thompson, Reid, Bailey, Simon, Lindsey, Janet, Di Rocco, Concezio, Massimi, Luca, Michiels, Erna, Scherer, Stephen, Lee, Ji-Yeoun, Cho, Byung-Kyu, Kim, Seung-Ki, Wang, Kyu-Chang, Leonard, Jeffrey, Rubin, Joshua, de Torres, Carmen, Lavarino, Cinzia, Mora, Jaume, Cho, Yoon-Jae, Tabori, Uri, Olson, James, Gajjar, Amar, Packer, Roger, Fan, Xing, Muraszko, Karin, Vibhakar, Rajeev, Eberhart, Charles, Fouladi, Maryam, Lach, Boleslaw, Jung, Shin, Wechsler-Reya, Robert, Fèvre-Montange, Michelle, Jouvet, Anne, Jabado, Nada, Pollack, Ian, Rutkowski, Stefan, Pomeroy, Scott, French, Pim, Kloosterhof, Nanne, Kros, Johan, Van Meir, Erwin, Clifford, Steven, Bourdeaut, Franck, Delattre, Olivier, Doz, François, Hawkins, Cynthia, Malkin, David, Grajkowska, Wieslawa, Perek-Polnik, Marta, Bouffet, Eric, Rutka, James, Pfister, Stefan, Taylor, Michael, Gupta, Nalin, Phillips, Joanna, Weiss, William, and Liau, Linda

Subjects
Adolescent, Biomarkers, Tumor, Child, Child, Preschool, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 14, Cytogenetics, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Hedgehog Proteins, Humans, In Situ Hybridization, Fluorescence, Infant, Kruppel-Like Transcription Factors, Male, Medulloblastoma, Nuclear Proteins, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Proto-Oncogene Proteins c-myc, Reproducibility of Results, Risk Assessment, Risk Factors, Tissue Array Analysis, Wnt Proteins, Young Adult, Zinc Finger Protein Gli2
Abstract

PURPOSE: Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic differences among the four subgroups suggest that subgroup-specific molecular biomarkers could improve patient prognostication. PATIENTS AND METHODS: Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities around the world. Combined risk stratification models were designed based on clinical and cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping medulloblastoma tissue microarray (n = 453), with subsequent validation of the risk stratification models. RESULTS: Subgroup information improves the predictive accuracy of a multivariable survival model compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers (GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues, we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and Group 4 medulloblastomas. CONCLUSION: Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially improves patient prognostication, even in the context of heterogeneous clinical therapies. The prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials.

Published
2014

37. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.

Author

Grivas, Petros, Pouessel, Damien, Park, Chandler H., Barthelemy, Philippe, Bupathi, Manojkumar, Petrylak, Daniel P., Agarwal, Neeraj, Gupta, Sumati, Fléchon, Aude, Ramamurthy, Chethan, Davis, Nancy B., Recio-Boiles, Alejandro, Sternberg, Cora N., Bhatia, Astha, Pichardo, Cabilia, Sierecki, Mitch, Tonelli, Julia, Zhou, Huafeng, Tagawa, Scott T., and Loriot, Yohann

Published
2024
Full Text
View/download PDF

38. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer.

Author

Ricciuti, Biagio, Lamberti, Giuseppe, Puchala, Sreekar R., Mahadevan, Navin R., Lin, Jia-Ren, Alessi, Joao V., Chowdhury, Alexander, Li, Yvonne Y., Wang, Xinan, Spurr, Liam, Pecci, Federica, Di Federico, Alessandro, Venkatraman, Deepti, Barrichello, Adriana P., Gandhi, Malini, Vaz, Victor R., Pangilinan, Andy J., Haradon, Danielle, Lee, Elinton, and Gupta, Hersh

Published
2024
Full Text
View/download PDF

41. MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

Author

Gupta, Shilpa, Ballman, Karla V., Apolo, Andrea B., Sridhar, Srikala S., Chen, Ronald C., Wen, Yujia, Yen, Aihua Edward, Grivas, Petros, Tan, Alan, Baghaie, Shiva, Galsky, Matt D., Morris, Michael J., and Rosenberg, Jonathan E.

Published
2024
Full Text
View/download PDF

44. Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.

Author

Van Der Heijden, Michiel Simon, Powles, Thomas, Gupta, Shilpa, Bedke, Jens, Kikuchi, Eiji, De Wit, Ronald, Galsky, Matt D., Duran, Ignacio, Necchi, Andrea, Retz, Margitta, Yu, Evan Y., Hoffman-Censits, Jean H., Iyer, Gopa, Park, Se Hoon, Su, Wen-Pin, Parmar, Hema, Guan, Xuesong, Gorla, Seema Rao, Homet Moreno, Blanca, and Valderrama, Begoña Pérez

Published
2024
Full Text
View/download PDF

45. Factors predictive of primary resistance (PrimRes) to immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC).

Author

Pramod, Nikhil, Dawsey, Scott, Patgunarajah, Ubenthira, Lynn, David, Wei, Wei, Hobeika, Charbel, Nair, Monica, Martin, Allison, Maroli, Kimberly, Ornstein, Moshe Chaim, Wee, Christopher Eing, Gilligan, Timothy D., Nizam, Amanda, Bonham, Amanda, Mian, Omar Y., Pavicic, Paul G., Diaz-Montero, C. Marcela, and Gupta, Shilpa

Published
2024
Full Text
View/download PDF

47. Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.

Author

Grivas, Petros, Barata, Pedro C., Moon, Helen H., Gupta, Shilpa, Hutson, Thomas E., Sternberg, Cora N., Brown, Jason, Dave, Vaidehi, Downey, Chad, Shillington, Alicia C., Katzenstein, Howard, Kirker, Melissa, Hanson, Sarah, Liu, Frank X., Morris, Valerie A., Bhanegaonkar, Abhijeet, and Sonpavde, Guru P.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results